logo
    • English
      • 简体中文
      • 繁體中文
  • Home
  • Articles
    • Insights
    • Client Press Releases
    • Client Coverage
  • Interviews
    • CEO Interview
    • PDAC Interview
  • Clients
    • Featured Companies
    • In-depth Analysis
  • Markets
    • Stock Tracker
    • Markets at a glance
    • Investing 101
      • Investing in Mining 101
        • Gold and Precious Metals
        • Electric and Battery Metals
        • Base Metals
        • Other Mining Subsectors
  • METALS 100
  • GCFF Event
    • Next Event
    • Past Events
  • Home
  • Market News
  • China Makes Over 1.7 Million Covid-19 Testing Kits per Day, Official Says

China Makes Over 1.7 Million Covid-19 Testing Kits per Day, Official Says

中国日产逾170万份新冠肺炎检测试剂
Published on: Feb 24, 2020
Author: Amy Liu
  • Share article:

China is  producing 1.7 million nucleic acid-based tests and 350,000 antibody test kits  each day to detect Covid-19 infections, according to a deputy director of the  National Medical Products Administration.
The daily output of protective suits  has reached 330,000 units per day and that of face masks is up to 844,000, Yan  Jiangying said at a press conference today.
Source: Yicai Global

Suggested Opportunity

Rakovina Therapeutics Inc.

Rakovina Therapeutics Inc. (TSXV: RKV)

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

Healthcare Services

Related Posts

Bullish 上市首日暴涨 84%,Ark Invest 重仓押注加密赛道

Seize the Golden Window for Biotech IPOs, Attovia Aims to Raise Up to $212.5 Million in Nasdaq Debut

强生公司股票当前是否值得买入?

Johnson & Johnson Quietly Completes Strategic Pivot, Targeting $50 Billion Cancer Drug Blueprint

Can Amgen’s Monthly Obesity Shot Rattle the Eli Lilly-Novo Nordisk Duopoly?

Can Amgen’s Monthly Obesity Shot Rattle the Eli Lilly-Novo Nordisk Duopoly?

电网科技股已成投资新焦点

Capital Expenditure Surge Reshapes Market Landscape as Funds Flee Tech Stocks for Value Opportunity in Healthcare

Moderna正在等待重要疫苗审批,这是该股的一次机会吗?

Moderna’s Market Value Exceeds Twenty Billion Dollars, Yet Ongoing Operating Losses and Competitive Pressures Continue to Trouble Investors

百时美施贵宝押注未来,哪些管线将成为新增长支柱?

Bristol-Myers Squibb’s High Dividend Temporarily Backed by Financial Support, but Patent Cliff Poses Future Concerns

Related News

Seize the Golden Window for Biotech IPOs, Attovia Aims to Raise Up to $212.5 Million in Nasdaq Debut

13 hours ago.

Johnson & Johnson Quietly Completes Strategic Pivot, Targeting $50 Billion Cancer Drug Blueprint

15 hours ago.

Can Amgen’s Monthly Obesity Shot Rattle the Eli Lilly-Novo Nordisk Duopoly?

16 hours ago.

Intuitive Surgical Down 44%: Wall Street Eyes a Double-Your-Money Rebound

2 days ago.

Top Stories

Nvidia vs. Apple: Inside the $5 Trillion Battle for Market Cap Supremacy
Technology

Nvidia vs. Apple: Inside the $5 Trillion Battle for Market Cap Supremacy

AI推理浪潮来袭,美光抢占千亿内存市场
Technology

Executive Sell-Off Wave Sweeps Semiconductor Sector, Micron Shares Pull Back Over 30% from Peak

We connect Investors to Opportunities.

Financial Market Data copyright © 2020 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.

 
QuoteMedia logo

Head Office

  • 2209 – 1111 Alberni Street
    Vancouver, BC Canada V6E 4V2
  • Phone: (604) 488-8878
  • Fax: (604) 488-0868
  • Toll Free: 1 (866) 833-5517
  • Email: [email protected]

Shanghai Office

  • 06 - 607, 6/f. No.800 Shangcheng
    Road Pudong New District Shanghai,
    China
  • Phone: 021-68883919
  • Fax: 021-68882879
  • Email: [email protected]

Important Links

  • Privacy Policy
  • Terms of Use
  • Content Partner
  • NAI500 Investor Relations Services
  • About Us
  • Contact Us

© 2026 NAI Interactive Ltd. All Rights Reserved

gcff

logo

Website Design Vancouver by Nirvana Canada